India's Sun Pharmaceutical Reportedly Bids $12B to Acquire Women's Healthcare Firm Organon

Organon shares surge 15% on reports of the potential takeover deal.

Apr. 10, 2026 at 1:25pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a polished, geometric glass bottle or vial in the center of the frame, representing a pharmaceutical product, floating on a clean, monochromatic seamless background and illuminated by dramatic studio lighting.A potential $12 billion acquisition of women's healthcare firm Organon could help India's Sun Pharmaceutical expand its branded drug portfolio.Jersey City Today

Shares of Organon, a women's healthcare company based in Jersey City, New Jersey, surged 15% in premarket trading on Friday following reports that India's Sun Pharmaceutical Industries has submitted a binding offer to acquire the firm for $12 billion.

Why it matters

The potential acquisition would mark Sun Pharmaceutical's most ambitious overseas deal as it looks to expand its branded and innovative drug portfolio. For Organon, the deal could provide a significant premium over its current $2 billion market value and help offset its recent revenue declines.

The details

According to The Economic Times, which cited unnamed sources, Sun Pharmaceutical has decided to proceed with a binding offer of $12 billion to acquire Organon. Organon, which has an enterprise value above $9 billion, reported revenue of over $6 billion in 2025, down 3% year-over-year, and projected similar sales for the current year.

  • Organon shares were down roughly 40% over the past year heading into Friday's session.
  • Organon reported 2025 revenue of over $6 billion in February 2026.

The players

Sun Pharmaceutical Industries

An Indian multinational pharmaceutical company that is reportedly making a $12 billion bid to acquire Organon.

Organon

A women's healthcare company based in Jersey City, New Jersey, that has a market value of around $2 billion and an enterprise value above $9 billion.

Got photos? Submit your photos here. ›

What’s next

If the deal is approved, it would mark Sun Pharmaceutical's most ambitious overseas acquisition as the company looks to expand its branded and innovative drug portfolio.

The takeaway

The potential $12 billion acquisition of Organon by Sun Pharmaceutical highlights the ongoing consolidation in the women's healthcare industry, as larger pharmaceutical firms seek to bolster their product pipelines and diversify their revenue streams.